|
S1119
|
XL-184 free base (Cabozantinib) |
XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
|
|
|
S1010
|
BIBF1120 (Vargatef) |
BIBF1120 (Vargatef) is a potent inhibitor of VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
|
|
|
S1046
|
Vandetanib (Zactima) |
Vandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM. |
|
|
|
S1035
|
Pazopanib HCl |
Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. |
|
|
|
S1005
|
Axitinib |
Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. |
|
|
|
S7082
|
TAK-593 |
TAK-593 is a novel dual VEGFR/PDGFR inhibitor. |
|
|
|
S4001
|
Cabozantinib malate |
Cabozantinib malate is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
|
|
|
S2018
|
ENMD-2076 L-(+)-Tartaric acid |
ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, a selective inhibitor of Aurora A and Aurora B with IC50 of 14 nM and 350 nM and also inhibits Flt3, Flt4 and VEGFR2 with IC50 of 1.86 nM, 15.9 nM and 58.2 nM, respectively. |
|
|
|
S1040
|
Sorafenib (Nexavar) |
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
|
|
|
S1042
|
Sunitinib Malate (Sutent) |
Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
|
|
|
S2859
|
Golvatinib (E7050) |
E7050 is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, respectively. |
|
|
|
S1018
|
Dovitinib (TKI-258) |
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
|
|
|
S3012
|
Pazopanib |
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-α/β, and c-Kit. |
|
|
|
S2897
|
ZM 306416 |
ZM-306416 is a VEGFR inhibitor, inhibiting Src, VEGFR1 and Abl with IC50 of 0.33 μM, 0.33 μM and 1.3 μM, respectively. |
|
|
|
S2896
|
ZM 323881 HCl |
ZM-323881 is a potent and selective inhibitor of VEGFR2 with IC50 < 2 nM. |
|
|
|
S2842
|
SAR131675 |
SAR131675 is a VEGFR-3 inhibitor with IC50 of 20 nM. |
|
|
|
S2845
|
Semaxanib (SU5416) |
Semaxanib (SU5416) is a potent and selective VEGFR (Flk-1/KDR) inhibitor with IC50 of 1.04 μM. |
|
|
|
S2221
|
Apatinib (YN968D1) |
Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM. |
|
|
|
S2231
|
Telatinib (BAY 57-9352) |
Telatinib (BAY 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRβ with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. |
|
|
|
S2202
|
NVP-BHG712 |
NVP-BHG712 is a specific inhibitor of c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM and also inhibits EphB4 and VEGFR2 with ED50 of 25 nM and 4.2 μM, respectively. |
|
|
|
S2200
|
Raf265 derivative |
A derivative of Raf265. But the effects of this derivative is not known. |
|
|
|
S2201
|
BMS 794833 |
BMS794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 1.7 nM and 15 nM, respectively. |
|
|
|
S2161
|
RAF265 (CHIR-265) |
RAF265 (CHIR-265) is a selective and potent inhibitor of B-Raf and VEGFR2 with IC50 of 3-60 nM and EC50 of 30 nM, respectively. |
|
|
|
S1557
|
KRN 633 |
KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM and also inhibits PDGFRα/β with IC50 of 965 nM/9850 nM. |
|
|
|
S1486
|
AEE788 (NVP-AEE788) |
AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM and also inhibits VEGFR2 and Flt with IC50 of 77 nM and 59 nM, respectively. |
|
|
|
S1490
|
Ponatinib (AP24534) |
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
|
|
|
S1470
|
TSU-68 (SU6668) |
TSU-68 (SU6668, Orantinib) is a potent inhibitor of Flk-1/KDR, FGFR1 and PDGFRβ with Ki of 2.1 μM, 1.2 μM, and 8 nM, respectively. |
|
|
|
S1363
|
Ki8751 |
Ki8751 is a potent and selective inhibitor of VEGFR2, PDGFRα and c-Kit with IC50 of 0.9 nM, 67 nM and 40 nM, respectively. |
|
|
|
S1361
|
MGCD-265 |
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met, VEGFR1, VEGFR2, VEGFR3, Ron, and Tie2 with IC50 of 1 nM, 3 nM, 3 nM, 4 nM, 2 nM and 7 nM, respectively. |
|
|
|
S1264
|
PD173074 |
PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM. |
|
|
|
S1220
|
OSI-930 |
OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively. |
|
|
|
S1207
|
Tivozanib (AV-951) |
AV-951 (Tivozanib, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 0.21 nM/0.16 nM/0.24 nM and also inhibits PDGFR and c-Kit with IC50 of 1.72 nM and 1.63 nM, respectively.
|
|
|
|
S1181
|
ENMD-2076 |
ENMD-2076 is a selective inhibitor of Aurora A and Aurora B with IC50 of 14 nM and 350 nM and also inhibits Flt3, Flt4 and VEGFR2 with IC50 of 1.86 nM/15.9 nM and 58.2 nM, respectively. |
|
|
|
S1178
|
Regorafenib (BAY 73-4506) |
Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
|
|
|
S1171
|
CYC116 |
CYC116 is a potent inhibitor of Aurora A/B and VEGFR with Ki of 8.0 nM/9.2 nM and 44 nM, respectively. |
|
|
|
S1164
|
E7080 (Lenvatinib) |
E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively. |
|
|
|
S1138
|
Brivanib alaninate (BMS-582664) |
BMS-582664 is an oral VEGFR/FGFR inhibitor for VEGFR2, Flk1, VEGFR1 and FGFR1 with IC50 of 25 nM, 89 nM, 380 nM and 148 nM, respectively. |
|
|
|
S1111
|
Foretinib (GSK1363089, XL880) |
XL880 (GSK1363089, EXEL-2880) is an ATP-competitive inhibitor of MET and KDR with IC50 of 0.4 nM and 0.9 nM, respectively. |
|
|
|
S1101
|
Vatalanib 2HCl (PTK787) |
Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR, Flt-1 and c-Kit with IC50 of 37 nM, 77 nM and 730 nM, respectively. |
|
|
|
S1084
|
Brivanib (BMS-540215) |
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively. |
|
|
|
S1032
|
Motesanib Diphosphate (AMG-706) |
Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3, PDGFR, c-Kit and Ret with IC50 of 2 nM/3 nM/6 nM, 84 nM, 8 nM and 59 nM, respectively. |
|
|
|
S2769
|
Dovitinib Dilactic acid (TKI258 Dilactic acid) |
Dovitinib (TKI258, CHIR-258) is a multitargeted tyrosine kinase inhibitor of FLT3 and c-KIT with IC50 of 1 nM and 2 nM, respectively. |
|
|
|
S1017
|
Cediranib (AZD2171) |
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
|
|
|
S1003
|
Linifanib (ABT-869) |
Linifanib (ABT-869) is a novel, potent ATP-competitive RTK inhibitor for KDR, CSF-1R, Flt-1, Flt-3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM, 3 nM, and 66 nM respectively. |
|
|